EMA Authorised: Dafiro HCT (valsartan;hydrochlorothiazide;amlodipine besilate) — Novartis Europharm Limited

View source ↗

Summary

The EMA has authorised Dafiro HCT, a fixed-dose combination of valsartan, hydrochlorothiazide and amlodipine besilate, for the treatment of hypertension. The ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Dafiro HCT

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Novartis Europharm Limited. Decision date: 05/02/2026